TravelC Group

Under the flag of TravelC Group, a company has been established for several internationally operating leisure brands. The Group consists of several complementary companies that facilitate the synergy between online, offline and personal attention within the Dutch travel industry.

The Group currently has an annual turnover of approximately € 400 million and consists of more than 600 travel specialists, more than 250 thousand bookings annually, more than 89 million visitors and serves more than 8 million travelers annually. The Travel Company and The Travel Club maintain the largest network in the Netherlands of 400 Independent Travel Advisors (ZRAs).

The ambition is to further grow this Group in the coming years into the leading travel organization in the field of technology, product range and customer experience. New acquisitions must also increase one of these pillars.

We hold a majority interest in TravelC Group.

Our news

9 April, 2026

819 Capital Partners invests in Wolk

Deventer, 9 April 2026 - Dutch company Wolk has raised €1.75 million to accelerate the deployment of its smart hip airbag in elderly care. The investment round was led by 819 Capital Partners, through 819 Seed Fund I, and the Innovatiefonds Ouderenzorg of CbusineZ (CZ), with participation from Nivogé, Catalyst Impact Investment Club, and several angel investors. Each year in the Netherlands, approximately 120,000 elderly people end up in the emergency department after a fall....

Continue reading
6 March, 2026

819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations

Deventer, 6 March 2026 - 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs. The transaction includes intellectual property rights, research data, and selected development programs. Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies...

Continue reading